Thursday 16 October, 2025
Objective: Drug repurposing is gaining attention in cancer therapy development by using safe, approved drugs, speeding up development and reducing…
Read morePoster: Drug/Disease Modelling - Oncology
QSP Platform Model for Predicting Clinical Efficacy & CRS in CD3xHLA-G T-Cell Engagers (TCEs) for Solid Tumors
Thursday 16 October, 2025
Background: CD3 bispecific antibodies (CD3-BsAbs) engage T cells to selectively recognize and eliminate cancer cells. However, their potent immune activation…
Read moreA Semi-Mechanistic Longitudinal Gaussian Process Regression Model for Estimating Tumor Response to Treatment
Thursday 16 October, 2025
Recent advances in oncology have spurred the development of semi-mechanistic models to better understand tumor-size response to treatment. Traditional approaches,…
Read moreProspective validation of an EGFR-Mutated NSCLC mechanistic computational disease model: predicting the combination treatment efficacy of phase III clinical trial
Thursday 16 October, 2025
Introduction Targeted therapies have significantly improved outcomes for patients with EGFR-mutated non-small cell lung cancer (NSCLC), yet acquired resistance limits…
Read moreCharacterizing the organ-specific association between tumor dynamics and overall survival across cancer types and studies: a Bayesian meta-regression
Thursday 16 October, 2025
Context: In oncology clinical trials, the primary clinical endpoint is often overall survival (OS), requiring prolonged study durations. Tumor size…
Read moreAssessing tobemstomig binding dynamics through integrated experimental and computational modeling approaches to inform therapeutic dosing
Thursday 16 October, 2025
INTRODUCTION: Tobemstomig is a 1+1 PD1-LAG3 bispecific antibody aiming to reinvigorate tumor-specific T-cells and overcome LAG3-mediated resistance to current checkpoint…
Read moreOperating Characteristics of M-protein Dynamic Metrics to Support Early Decisions in Multiple Myeloma
Thursday 16 October, 2025
Introduction: Model-derived tumor dynamic metrics have shown promise in predicting overall survival (OS) [1,2,3] to support late-stage drug development (DD)….
Read moreProjecting median survival times for studies with immature survival data to support accelerated approval considerations of treatments in multiple myeloma
Thursday 16 October, 2025
Introduction: The treatment landscape in relapsed/refractory multiple myeloma (RRMM) has seen improvement in recent years, with new therapies often receiving…
Read moreA Physiologically Based Pharmacokinetic Model for Cisplatin in Metastatic EGFR-Mutated NSCLC: Application and prospective validation in the context of FLAURA2 Phase III
Thursday 16 October, 2025
Introduction First-line EGFR tyrosine kinase inhibitors (TKIs) such as osimertinib offer improved survival in EGFR-mutated NSCLC, yet acquired resistance ultimately…
Read morePopulation Pharmacokinetic and Pharmacodynamic modeling Analysis of rhIL-7-hyFc, a hybrid Fc-Fused Long-Acting Interleukin-7, to support Optimal Dose Regimens in Patients with Solid Cancer
Thursday 16 October, 2025
Objective: rhIL-7-hyFc (Efineptakin alfa) is a newly developed long-acting recombinant human interleukin-7, designed to amplify and enhance the number of…
Read more